REFERENCES
1. Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract . 2018 Jul-Aug;6(4):1274-1286.
2. Wheatley L, Togias A. Clinical practice. Allergic rhinitis . N Engl J Med. 2015 Jan 29;372(5):456-63.
3. Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy Asthma Clin Immunol . 2020 May 27;16:39.
4. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol . 1993 Sep 1;151(5):2623-32.
5. Casale TB. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am J Respir Crit Care Med . 2001 Oct 15;164(8 Pt 2):S18-21.
6. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract . 2014 May-Jun;2(3):332-40.e1.
7. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ . 2011 Oct 18;343:d5928.
8. Bez C, Schubert R, Kopp M, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy . 2004;34(7):1079-85.
9. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy . 2004 Sep;59(9):973-9.
10. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol . 2002;109(2):274-80.
11. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy . 2009;39(2):271-9.
12. Nagakura T, Ogino S, Okubo K, Sato N, Takahashi M, Ishikawa T. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy . 2008;38(2):329-37.
13. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int . 2006;55(4):379-86.
14. Okubo K, Okano M, Sato N, et al. Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized Study. J Allergy Clin Immunol Pract . 2020;8(9):3130-40 e2.
15. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.J Allergy Clin Immunol . 2000;106(2):253-9.
16. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol . 2003 Aug;91(2):160-7.
17. Higaki T, Okano M, Kariya S, et al. Determining minimal clinically important differences in Japanese cedar/cypress pollinosis patients. Allergol Int . 2013 Dec;62(4):487-93.
18. Okubo K, Kurono Y, Ichimura K, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int . 2020 Jul;69(3):331-345.
19. Nakamura S, Tsunoda S, Sakaida H, Masuda S, Said AS, Takeuchi K. Analysis of factors associated with cedar pollen sensitization and development of pollinosis in a young Japanese adult population.Allergol Int . 2019 Jan;68(1):39-45.
20. Gotoh M, Yuta A, Okano M, Ohta N, Ohta N, Matsubara A, Matsubara A, Okubo K. Severity assessment of Japanese cedar pollinosis using the practical guideline for the management of allergic rhinitis in Japan and the allergic rhinitis and its impact on asthma guideline. Allergol Int . 2013 Jun;62(2):181-9.
21. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol . 2006;117(1):134-40.
22. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol . 2010;21(1 Pt 2):e160-5.
23. New Drugs Approved in FY 2019. Available at:https://www.pmda.go.jp/files/000235289.pdf
24. Yu C, Wang K, Cui X, et al. Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Am J Rhinol Allergy . 2020 Mar;34(2):196-208.
25. Cavaliere C, Begvarfaj E, Incorvaia C, et al. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett . 2020 Nov;227:81-87
26. Casale TB, Bernstein Il, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.J Allergy Clin Immunol . 1997 Jul;100(1):110-21
27. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.JAMA . 2001 Dec 19;286(23):2956-67.
28. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy . 2004 Jul;59(7):709-17.
Table I General Characteristics of included studies